New Delhi, Sep 28 (PTI) Zydus Lifesciences on Saturday said it has received approval from the US health regulator to produce generic prostate cancer treatment drug.

The company has received approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide capsules (40 mg), it said in a regulatory filing.

Also Read | Noida Shocker: 62-Year-Old Man Kills Wife with Iron Rod, Faces Charges Under Section 105 of Bharatiya Nyaya Sanhita, Arrested.

Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer.

The drug will be produced at the group's manufacturing site in Moraiya, Ahmedabad, Zydus said.

Also Read | 7th Pay Commission: Tamil Nadu Govt Likely to Announce 4% DA Hike For Its Employees Ahead of Diwali, Says Report.

As per IQVIA MAT July 2024 data, Enzalutamide capsules (40 mg) had annual sales of USD 869.4 million in the US.

The group now has 400 approvals and has filed over 465 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)